重大事件
即時報告
8-K
2026-06-22
Atea Pharmaceuticals年度股東大會通過全部三項議案 包括董事選舉及KPMG續聘
AI 繁中摘要
📄 **Atea Pharmaceuticals 提交8-K表格：2026年度股東大會投票結果出爐**
生物製藥公司Atea Pharmaceuticals（納斯達克代號：AVIR）於2026年6月18日舉行年度股東大會，並於6月22日向SEC提交8-K報告披露投票結果。出席或由委託書代表的股份總數為59,742,819股，約佔已發行普通股的74.65%。
**三項議案全部獲得通過** ✅
1. **選舉三名第三類董事**（任期至2029年年度股東大會）：
- Jerome Adams, MD, MPH：贊成28,798,012票，反對22,275,665票，經紀人未投票8,669,142票
- Howard Berman, PhD：贊成44,466,627票，反對6,607,050票，經紀人未投票8,669,142票
- Barbara Duncan：贊成43,697,098票，反對7,376,579票，經紀人未投票8,669,142票
三位候選人順利當選。
2. **批准聘任KPMG LLP為2026年度獨立註冊會計師事務所**：
- 贊成58,894,207票，反對783,081票，棄權65,531票，無經紀人未投票。獲得通過。
3. **諮詢性投票通過高層管理人員薪酬（Say-on-Pay）**：
- 贊成47,452,759票，反對2,977,290票，棄權643,628票，經紀人未投票8,669,142票。獲得通過。
**對投資者的潛在影響** 🧐
本次會議所有議案均獲股東支持，顯示公司治理與高管薪酬安排獲得機構投資者及散戶的認可。特別是KPMG的續聘及董事會成員連任，有助維持財務報告的獨立性與戰略穩定性。留意到Jerome Adams醫生的贊成票數相對較低（約56%），反映部分股東對其提名可能存有顧慮，但整體無礙公司管治正常運作。
展開英文正文
8-K false 0001593899 0001593899 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2026 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number) 225 Franklin Street Suite 2100 Boston, MA 02110 (Address of principal executive offices) (Zip Code) (857) 284-8891 (Registrant’s telephone number, include area code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share AVIR The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07. Submission of Matters to a Vote of Security Holders. On June 18, 2026, Atea Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 59,742,819 shares of the Company’s common stock were present in person or represented by proxy at the Annual Meeting, representing approximately 74.65% of the Company’s common stock outstanding as of the April 24, 2026 record date. Below are the final voting results certified by Broadridge Financial Solutions, Inc., the inspector of election, for the proposals considered and voted upon at the Annual Meeting. Each of these proposals were described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 27, 2026. Proposal 1 — Election of three Class III Directors to serve until the 2029 annual meeting of stockholders, and until their respective successors have been duly elected and qualified. FOR WITHHOLD BROKER NON-VOTE Jerome Adams, MD, MPH 28,798,012 22,275,665 8,669,142 Howard Berman, PhD 44,466,627 6,607,050 8,669,142 Barbara Duncan 43,697,098 7,376,579 8,669,142 Proposal 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. FOR AGAINST ABSTAIN BROKER NON-VOTE 58,894,207 783,081 65,531 0 Proposal 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTE 47,452,759 2,977,290 643,628 8,669,142 Based upon the foregoing votes, Dr. Jerome Adams, Dr. Howard Berman and Barbara Duncan were elected as Class III directors and Proposals 2 and 3 were approved. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATEA PHARMACEUTICALS, INC. Date: June 22, 2026 By: /s/ Andrea Corcoran Andrea Corcoran Chief Financial Officer and Executive Vice President, Legal and Secretary